You are viewing a preview of...

Chimeric 3C-RBD Recombinant COVID-19 Vaccines to Enhance Cellular Immunity

A novel COVID vaccine based on a recombinant chimer that is more soluble, stable and easier to produce

Background

SARS-CoV-2 is the newly emerging member of the Coronaviridae (CoV) family, responsible for the Coronavirus disease-2019 (COVID-19) pandemic. Person-to-person transmission of the virus resulted in rapid spreading of SARS-CoV-2 worldwide. it is reported that SARS-CoV-2 has resulted in more than 86 million infections and almost 4 million deaths already around the world.

SARS-CoV-2 is an enveloped virus that contains a single-stranded positive-sense RNA. Infection begins when the virus attaches to pulmonary cells via the angiotensin converting enzyme 2 (ACE-2) receptor mediated by a glycoprotein expressed on its surface, the Spike protein (Spro) (Letko et al., 2020). Fusion of the viral membrane with the lumen of the endosomal membrane leads to endocytosis, facilitating infection via entry of the viral

Log in or create a free account to continue reading